Also, increased GSK-3β expression might be associated with resistance to TMZ and poor prognosis in glioma patients by decreasing MGMT promoter methylation and thus upregulation of MGMT (Pyko et al. 2013; Tian et al. 2016; Cai et al. 2018). Here, GSK3B is linked to glioma.